Serotonin Release in Premotor and Motor PD

NCT05516732 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2025-10-07

No results posted yet for this study

Summary

In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms

Conditions

Interventions

OTHER

Positron Emission Tomography (PET) scan using CIMBI-36 tracer

This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.

OTHER

Magnetic Resonance Imaging (MRI) Scan

MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain

OTHER

Positron Emission Tomography (PET) scan using DASB tracer

To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.

OTHER

FP-CIT Single-photon Emission Computed Tomography (SPECT) scan

A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.

OTHER

Lumbar puncture

A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)

Sponsors & Collaborators

  • University of Exeter

    lead OTHER

Principal Investigators

  • Marios M Politis, Professor · University of Exeter

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516732 on ClinicalTrials.gov